Home > Insider Trading > Filing (0001209191-21-005222)

Filing Details

Accession Number:: 0001209191-21-005222
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2021-01-25 19:00:09
Reporting Period:: 2021-01-19

Accepted Time:: 2021-01-25 19:00:09
Original Submission Date:: 2021-01-21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1478320	Adaptive Biotechnologies Corp	ADPT	Biological Products, (No Disgnostic Substances) (2836)	270907024

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1780851	S Harlan Robins	C/O Adaptive Biotechnologies Corp. Suite 200 Seattle WA 98102	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-19	50,000	$6.55	50,679	No	4	M	Direct
Common Stock	Disposition	2021-01-19	31,146	$67.02	19,533	No	4	S	Direct
Common Stock	Disposition	2021-01-19	3,001	$67.74	16,532	No	4	S	Direct
Common Stock	Disposition	2021-01-19	5,701	$69.26	10,831	No	4	S	Direct
Common Stock	Disposition	2021-01-19	8,052	$69.97	2,779	No	4	S	Direct
Common Stock	Disposition	2021-01-19	2,100	$70.75	679	No	4	S	Direct
Common Stock	Acquisiton	2021-01-20	50,000	$6.55	50,679	No	4	M	Direct
Common Stock	Disposition	2021-01-20	20,394	$66.84	30,285	No	4	S	Direct
Common Stock	Disposition	2021-01-20	24,945	$67.39	5,340	No	4	S	Direct
Common Stock	Disposition	2021-01-20	4,661	$68.20	679	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-19	50,000	$0.00	50,000	$6.55
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-20	50,000	$0.00	50,000	$6.55

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
350,000		2028-02-07	No	4	M	Direct
300,000		2028-02-07	No	4	M	Direct

Footnotes

These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.39 to 67.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $67.42 to 68.20, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $68.54 to 69.53, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $69.54 to 70.50, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $70.54 to 71.02, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.07 to 67.06, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $67.07 to 68.06, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $68.07 to 68.48, inclusive.
The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.